Genetic determinants of platelet response to clopidogrel by Kubica, Aldona et al.
Genetic determinants of platelet response to clopidogrel
Aldona Kubica • Marek Kozinski • Grzegorz Grzesk •
Tomasz Fabiszak • Eliano Pio Navarese •
Aleksander Goch
Published online: 26 June 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Antiplatelet agents are the mainstay treatment
in the prevention and management of atherothrombotic
complications. However, a substantial interpatient vari-
ability in response to clopidogrel has been reported. Fur-
thermore, patients with coronary artery disease and lesser
platelet inhibition in response to clopidogrel are at
increased risk for cardiovascular events. Clopidogrel after
absorption requires two-step oxidation by the hepatic
cytochrome P450 to generate its active metabolite. Poly-
morphisms of genes encoding the cytochrome enzymes and
P-glycoprotein involved in clopidogrel absorption are
regarded as major determinants of the interindividual var-
iability in the clopidogrel-induced platelet inhibition. In
our review we discuss the prevalence and clinical signiﬁ-
cance of various alleles of the genes: CYP2C19 and
ABCB1 in the setting of coronary artery disease. Allele
CYP2C19*2 is associated with excess of ischaemic events
including myocardial infarction and stent thrombosis. On
the other hand, CYP2C19*17 allele poses a serious threat
of bleeding. Data concerning the prognostic value of
genetic variant 3435C?T of ABCB1 remain inconclusive.
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Introduction
Several large clinical trials have shown that clopido-
grel effectively prevents thrombotic events in patients
with atherosclerotic vascular disease [1–4]. Clopidogrel
administration combined with aspirin is a standard therapy
in acute coronary syndromes and after stent implantation.
However, pharmacodynamic response to clopidogrel has
substantial interpatient variability, and patients with coro-
nary disease and lesser platelet inhibition in response to
clopidogrel appear to be at increased risk for cardiovas-
cular events [5–11].
There are several possible mechanisms of clopidogrel
response variability or ‘‘resistance’’ [12, 13]. If a patient is
not taking clopidogrel or taking it only intermediately, the
patient will appear by platelet function testing to be hyp-
oresponsive or resistant to clopidogrel. Other drugs may
interfere with clopidogrel metabolism through hepatic
cytochrome P450. Single nucleotide polymorphism may
modulate platelet response to clopidogrel therapy [14].
Other factors modifying response to clopidogrel should be
also taken in account, e.g. accelerated platelet turnover,
with introduction into bloodstream of newly formed, drug-
unaffected platelets that can strongly inﬂuence antiplatelet
effect of clopidogrel [15]. Numerous clinical conditions
such as elderly age, diabetes mellitus, decreased left ven-
tricular function, renal failure, and acute coronary syn-
drome are associated with an impaired antiplatelet action of
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idogrel effectiveness cannot be excluded because arterial
thrombosis is a multifactorial phenomenon, not solely
dependent on P2Y12 activation [16–19].
In this review we discuss genetic background of platelet
response to clopidogrel and its clinical signiﬁcance in
patients with coronary artery disease.
Genetic background of clopidogrel metabolism
Clopidogrel, like all thienopyridines, is an inactive pro-
drug. It requires two-step oxidation by the hepatic cyto-
chrome P450 to generate its active thiol metabolite. The
metabolite targets and irreversibly inhibits P2Y12 receptor.
Esterases shunt the remaining prodrug to an inactive
pathway. The genes encoding the cytochrome enzymes are
polymorphic, and there are some genetic variants that
diminish transformation into the active metabolite (Fig. 1).
Several studies have established that CYP2C19 genotyping
identiﬁes more than 90% of poor clopidogrel metabolizers,
indicating good genotype–phenotype agreement [10, 20].
There are 25 known polymorphic variants of the
CYP2C19 gene, with the frequency varying among
different ethnic groups [21]. Some of these genetic variants
strongly inﬂuence the enzyme function (Table 1).
According to the allele present, the enzymatic activity of
CYP2C19 may be normal, reduced, or increased, resulting
in different plasma concentration of clopidogrel’s active
metabolite (Table 2)[ 22–24]. The CYP2C19*1 allele is the
normal (wild-type) copy that has full enzymatic activity.
The CYP2C19*2 and CYP2C19*3 alleles are the most
common variants resulting in complete loss of enzymatic
activity. Carriers of the *2 and *3 alleles have reduced
metabolism of clopidogrel and demonstrate diminished
clopidogrel-induced platelet inhibition. Other genetic
variants of CYP2C19-*4 and *5, also result in no enzy-
matic activity, but their effect on platelet inhibition by
clopidogrel has not been fully documented [25–27].
Finally, the CYP2C19*17 allele results in increased
CYP2C19 activity, higher production of active metabolite,
and improved clopidogrel-induced platelet inhibition [23,
24, 28].
The prevalence of different CYP2C19 alleles varies by
ethnicity (Figs. 2, 3, Table 1). In the study published by
Sibbing et al. [29] 73% of patients in the German
population were CYP2C19 wild-type homozygotes
(CYP2C19*1/*1), 25% were heterozygotes with one
CYP2C19*2 allele and only 2% were homozygotes
(CYP2C19*2/*2). Almost the same frequencies were found
by Collet et al. [22] in the French population. Due to the
rare occurrence of the CYP2C19*2/*2 genotype, majority
of clinical analyses are based on the comparison between
wild-type homozygotes (CYP2C19*1/*1) and carriers of at
least one allele CYP2C19*2 (*1/*2 or *2/*2). CYP2C19*2
mutant allele are more common in other populations—
present in approximately 40% of Africans, and more than
55% of East Asians [9]. The proportion of patients who
carry at least one copy of CYP2C19*3 allele in Caucasians,
Africans, and Asians, is\1,\1, and 7%, respectively.
Other loss-of-function genetic variants of CYP2C19-*4
and *5 are rare in all ethnicities (\1%) [22]. Relatively
high frequencies of CYP2C19*17 allele were found: in
Germans 41% (36% heterozygotes and 5% homozygotes), Fig. 1 Genetic determinants of clopidogrel metabolism
Table 1 The most frequent CYP2C19 alleles and their impact on the
enzyme function
CYP2C19
allele
Nucleotide
change
Impact on the
enzyme function
Prevalence in
different
populations (%)
*1 None (wildtype) Normal
*2 681G[A Inactive 25–55
*3 636G[A Inactive 1–7
*4 1A[G Inactive \1
*5 1297C[T Inactive \1
*17 991A[G Increased 4–41
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123in French 20%, both in Swedes and Ethiopians 18%, and
only in 4% of Chinese [23, 24, 28].
The most frequent genetic functional variants of cyto-
chromeP4502C19enzyme:CYP2C19*2andCYP2C19*17
are important contributors to the wide interindividual vari-
abilityoftheantiplateleteffectofclopidogrel(Table 2).The
ﬁrst studies in this ﬁeld concerned CYP2C19 681 G[A*2
allelic variant encoding a cryptic splice site resulting in loss
of CYP2C19 enzyme activity.
Polymorphism of ABCB1, a gene encoding the P-gly-
coprotein involved in clopidogrel absorption, is another
emerging issue in the ﬁeld of cardiovascular genetics. The
genetic variant 3435C?T is associated with impaired
function of the intestinal drug-efﬂux transporter. The
prevalence of homozygotes CC, heterozygotes CT, and
homozygotes TT in the French population (n = 2,188) was
reported to be 25.8, 48.0, and 26.2%, respectively [30].
Relation of CYP2C19*2 allele to the platelet
inhibition by clopidogrel
Hulot et al. [25] evaluated platelet aggregation during and
after a 7-day course of clopidogrel according to the
CYP2C19 genotype in healthy volunteers. There were huge
Table 2 Expected effects of CYP2C19 polymorphism on clopidogrel metabolism
Genotype Expected effect on clopidogrel metabolism
CYP2C19*1/*1 Normal metabolizer—the subject is expected to demonstrate effective antiplatelet response to a standard dose of
clopidogrel
CYP2C19*1/*2 Intermediate metabolizer—the subject exhibits approximately half-normal enzyme activity, thus an increased
dosage of clopidogrel or an alternative treatment should be considered CYP2C19*1/*3
CYP2C19*1/*4
CYP2C19*1/*5
CYP2C19*2/*17 Normal/intermediate metabolizer—the subject is likely to have metabolic activity between normal and
intermediate metabolizers. In general, the response to a standard dose of clopidogrel should be sufﬁcient CYP2C19*3/*17
CYP2C19*4/*17
CYP2C19*5/*17
CYP2C19*2/*2 Poor metabolizer—the subject is characterized by a greatly decreased enzyme activity and may require an
alternative treatment or higher than standard dosage of clopidogrel to achieve required antiplatelet effect CYP2C19*2/*3
CYP2C19*2/*4
CYP2C19*2/*5
Or other conﬁguration of
these alleles
CYP2C19*1/*17 Rapid metabolizer—the subject have elevated enzyme activity and may be exposed to a higher concentration of
active drug metabolites resulting in increased bleeding risk
CYP2C19*17/*17 Ultra rapid metabolizer—the subject have markedly elevated enzyme activity. For prodrugs, like clopidogrel,
ultra rapid metabolizers are exposed to a higher concentration of active drug metabolites and may require
lower than standard dosage because of increased risk of bleeding
Fig. 2 CYP2C19*2 genotype frequency in the German (n = 2485),
French (n = 259), and Polish (n = 347) populations [22, 29, and
unpublished data of the authors]. *1-allele CYP2C19*1; *2-allele
CYP2C19*2
Fig. 3 CYP2C19*17 genotype frequency in the German (n = 1524),
French (n = 598), and Polish (n = 347) populations [24, 28, and
unpublished data of the authors]. *1-CYP2C19*1, *17-allele
CYP2C19*17
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123differences in ex vivo ADP-induced platelet aggregation
between carriers and noncarriers of the CYP2C19*2
mutant allele encoding a deﬁcient drug metabolizing
enzyme—a very good response after a 7-day course of
clopidogrel in wild-type homozygotes (CYP2C19*1/*1)
and impaired responsiveness in carriers of CYP2C19*2
mutant allele [25].
Mega et al. [9] showed that carriers of at least one
CYP2C19 reduced-function allele had relative reductions of
32.4 and 9% in plasma concentration of the active metab-
olite of clopidogrel and maximal platelet aggregation,
respectively, as compared with non-carriers. The pharma-
cokinetic and pharmacodynamic effects of CYP2C19
reduced-function allele on the response to clopidogrel were
observed after a loading dose (either 300 or 600 mg) and
during the administration of a maintenance dose (75 mg).
Carriers of a reduced-function CYP2B6allele alsotended to
have a lower pharmacokinetic and pharmacodynamic
response to clopidogrel [9].
These observations were conﬁrmed in a group of 797
consecutive patients undergoing percutaneous coronary
intervention, who were followed for 1 year [21]. Patients
carrying at least one CYP2C19*2 allele are more prone to
high platelet ADP-induced residual platelet aggregation
[21].
Impact of CYP2C19*2 polymorphism on the clinical
outcome
Because of the profound impact of genetic variation in
CYP2C19 activity on clopidogrel-induced inhibition of
platelet aggregation, there has been considerable investi-
gation in extending these observations to clinical outcomes.
The great impact of CYP2C19 polymorphism on clinical
outcome was shown by Collet et al. [22] in a population of
young patients after myocardial infarction treated with
clopidogrel. The ﬁnding of a strong relation between
presence of CYP2C19 reduced-function mutant allele
(CYP2C19*2) and recurrent coronary events was consistent
in a subset analysis, with both stent-related and stent-
independent coronary events. The primary endpoint (com-
posite of death, myocardial infarction, and urgent coronary
revascularization) occurred more frequently in carriers of
mutant allele than in non-carriers (HR 3.69; 95% CI
1.69–8.05; P = 0.0005), as did stent thrombosis (HR 6.02;
95% CI 1.81–20.04; P = 0.0009). Multivariable analysis
revealed that the presence of CYP2C19*2 allele was the
only independent predictor of cardiovascular events (HR
4.04; 95% CI 1.81–9.02; P = 0.0006) in young patients
receiving clopidogrel after myocardial infarction [22].
Another study of 2485 consecutive patients after coro-
nary stent placement revealed more than threefold higher
30-day incidence of stent thrombosis in CYP2C19*2
mutant allele carriers (*1/*2 or *2/*2) as compared with
CYP2C19*1 wild-type homozygous patients (P = 0.007)
[29]. The study also demonstrated that CYP2C19*2 carrier
status is an independent predictor for the occurrence of
stent thrombosis. Besides stent thrombosis, the cumulative
incidence of ST-segment elevation myocardial infarction
was signiﬁcantly higher in mutant allele carriers versus
wild-type homozygotes, so was the incidence of ischaemic
stroke. These results are corroborated by a gene-dose effect
of the CYP2C19*2 allele with homozygous allele carriers
(*2/*2) exhibiting the highest risk of stent thrombosis [29].
Similarly, Małek et al. [31] observed suboptimal
reperfusion and increased all-cause mortality in carriers of
the CYP2C19*2 allele treated with primary percutaneous
coronary intervention. The ﬁndings are in line with phar-
macodynamic [21, 32] and pharmacokinetic [33, 34]
investigations showing the strongest attenuation of platelet
response to clopidogrel for the mutant CYP2C19 allele
homozygotes (*2/*2).
The next proof of clinical signiﬁcance of CYP2C19
polymorphism in patients treated with clopidogrel comes
from the genetic substudy of TRITON-TIMI 38 (Trial to
assess improvement in therapeutic outcomes by optimizing
platelet inhibition with prasugrel TIMI 38) trial [9]. The
study provides genetic data for almost 1,500 patients
treated with clopidogrel. 395 (27.1%) of them were carriers
of at least one CYP2C19 reduced-function allele. In con-
cordance with pharmacokinetic and pharmacodynamic
ﬁndings, the risk of primary efﬁcacy outcome of death
from cardiovascular causes, myocardial infarction, or
stroke was signiﬁcantly higher in carriers as compared to
noncarriers—Fig. 4 (hazard ratio for carriers, 1.53; 95%
conﬁdence interval, 1.07–2.19; P = 0.01). No signiﬁcant
associations between any other CYP genotypes and clinical
outcome were observed. CYP2C19*2 allele carriers had a
higher rate of stent thrombosis than noncarriers (2.6 vs.
Fig. 4 Primary end point (cardiovascular death, myocardial infarc-
tion, stroke) in the TRITON-TIMI 38 trial (clopidogrel and prasugrel
arms—black bars) and in the TRITON-TIMI 38 genetic substudy in
clopidogrel arm in relation to CYP2C19 polymorphism (white bars)
[9, 36]. *1-allele CYP2C19*1, *2-allele CYP2C19*2
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1230.8%; hazard ratio for carriers 3.09; 95% conﬁdence
interval, 1.19–8.00; P = 0.02) [9].
Results of the pharmacokinetic and pharmacodynamic
studies mentioned above, combined by Mega et al. [9] with
clinical observations, provided strong evidence linking
polymorphism in the CYP2C19 gene with a reduced
exposure to the active clopidogrel metabolite, less platelet
inhibition, and as the consequence less protection from
ischemic events.
Well known TRITON-TIMI 38 study showed signiﬁ-
cantly better results in the prasugrel group as compared to
the whole group of patients treated with clopidogrel in
terms of primary efﬁcacy outcome of cardiovascular death,
myocardial infarction, and stroke [35]. Interestingly, the
primary efﬁcacy outcome in patients with favourable
genotype (noncarriers of CYP2C19*2 allele) treated with
prasugrel was comparable to this observed in patients
assigned to prasugrel therapy irrespectively of the genotype
(Fig. 4). In contrast to this ﬁnding, carriers of this mutant
allele treated with clopidogrel demonstrated a signiﬁcantly
higher incidence of primary efﬁcacy outcome as compared
to wild-type homozygotes (P = 0.01) [9, 36].
There are several other studies concerning the clinical
signiﬁcance of CYP2C19 polymorphism. Pooled data from
10 studies (11,959 patients) displayed a 30% increase in the
risk of major adverse cardiovascular events in carriers of
CYP2C19*2 [27]. This single gene variant was also asso-
ciated with an 80% excess in mortality (6,225 patients) and
3.5-fold higher risk of stent thrombosis (4,905 patients).
This increased risk was apparent in both heterozygotes and
homozygotes and was independent of the baseline cardio-
vascular risk [27]. Similarly, a recent meta-analysis of
9,685 patients on clopidogrel therapy treated predomi-
nantly with coronary stenting clearly indicates unfavorable
clinical outcome in carriers of CYP2C19*2 when com-
pared to noncarriers (Fig. 5)[ 36]. On the other hand, a
combined analysis of the genetic substudies of CURE
(clopidogrel in unstable angina to prevent recurrent events)
and ACTIVE (atrial ﬁbrillation clopidogrel trial with ir-
besartan for prevention of vascular events) trials suggests
that in patients on clopidogrel therapy treated mostly
conservatively, CYP2C19 polymorphism may not play any
major clinical role [37].
Theoretical considerations imply that a concomitant use
of proton pump inhibitors may competitively inhibit acti-
vation of clopidogrel by CYP2C19, thereby attenuating its
antiplatelet effect. However, a subanalysis of TRITON-
TIMI 38 trial failed to establish any clinical impact of
CYP2C19 polymorphism in patients treated with clopido-
grel and proton pump inhibitors [38]. Furthermore, in two
recent ex vivo studies coadministration of clopidogrel and
proton pump inhibitors led to a decreased antiplatelet effect
in all genetic subsets [39, 40]. However, the attenuation of
clopidogrel antiplatelet activity was paradoxically least
pronounced in carriers of a loss-of-function allele.
Potential strategies dedicated to overcome genetic
clopidogrel resistance
Numerous strategies to facilitate platelet inhibition in car-
riers of a reduced-function alleles were proposed. The
simplest ones include an increase of clopidogrel loading
and/or maintenance doses, and switching to ticlopidine.
Although such changes decrease platelet aggregation, their
favourable clinical impact has not been convincingly pro-
ven so far [41, 42].
Other therapeutic options include switching to a more
potent P2Y12 inhibitor, use of hepatic cytochrome P450—
independent agents, and additional blockade of alternative
platelet activation pathways.
As mentioned previously, according to the genetic
substudy of TRITON-TIMI 38 trial, prasugrel confers
clinical beneﬁts only in clopidogrel poor metabolizers [9].
On the other hand, ticagrelor, a direct and reversible
P2Y12 inhibitor, decreases prevalence of ischaemic events
irrespectively of the CYP2C19 genotype, as shown in the
genetic substudy of PLATO (the platelet inhibition and
patient outcomes) trial [43]. Cangrelor and elinogrel are
other potent reversible P2Y12 inhibitors which do not
require activation and may be particularly effective in
clopidogrel poor metabolizers. However, in two large-scale
international phase III trials in patients undergoing percu-
taneous coronary interventions intravenous therapy with
cangrelor was comparable in terms of the clinical efﬁ-
ciency to 600 mg of oral clopidogrel [44] and intravenous
pretreatment with cangrelor before administration of a
Fig. 5 Occurrence of ischaemic events in patients treated with
clopidogrel in relation to the CYP2C19*2 polymorphism in the
metaanalysis (n = 9685) conducted by Mega et al. [37]. CV
cardiovascular death, MI myocardial infarction
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123loading dose of clopidogrel was not superior to placebo in
reducing ischaemic events [45]. Interestingly, elinogrel is
suitable for both acute intravenous and long-term oral
therapy. In an unpublished phase IIb clinical study—
INNOVATE-PCI, elinogrel when compared with clopido-
grel achieved a more rapid and potent platelet inhibition
with similar rates of bleedings and clinical and biological
efﬁcacy end-points in patients treated with elective coro-
nary stenting.
Cilostazol, an inhibitor of phosphodiesterase 3, when
added to a standard clopidogrel maintenance dose, sup-
presses ADP-dependent platelet aggregation more effec-
tively than a high clopidogrel maintenance dose in patients
with high post-treatment platelet reactivity undergoing
coronary stenting [46]. However, no genetic analysis was
performed in this study.
Similarly, periprocedural glycoprotein IIb/IIIa receptor
blockade with tiroﬁban in patients undergoing elective
coronary stenting successfully reduced ischemic events
among those resistant to clopidogrel and/or aspirin [47]. In
this study patients were assigned to tiroﬁban or placebo on
the basis of platelet function evaluation with a point-of-
care assay, without CYP2C19 genotyping.
Signiﬁcance of CYP2C19*17 polymorphism
In 2006 Sim et al. [23] identiﬁed a novel allele
(CYP2C19*17) carrying mutations: –806C[T and
–3402C[T. In an experimental study they showed
increased transcriptional activity of the CYP2C19*17
allele in vivo in mice. The presence of CYP2C19*17 allele
results in ultrarapid metabolism of all CYP2C19 substrates.
Frere et al. [24] evaluated the impact of clopidogrel
extensive metabolism in the presence of CYP2C19*17
allelic variant on platelet response to the drug in patients
suffering from non-ST elevation acute coronary syndrome.
The observed frequency of the CYP2C19*17 allele in the
group of 449 patients was 20%. The CYP2C19*17 allele
carriers exhibited the lowest vasodilator stimulated phos-
phoprotein phosphorylation index PRI VASP (mean ± SD
49.7 ± 23.7 vs. 55.9 ± 22.8), testifying a better platelet
response to a 600 mg loading dose of clopidogrel [24].
These ex vivo results were conﬁrmed in vivo by Sibbing
et al. [28].
They assessed the impact of CYP2C19*17 on ADP-
induced platelet aggregation, the risk of bleeding, and stent
thrombosis occurrence in clopidogrel-treated patients
undergoing percutaneous coronary intervention. The study
population consisted of 1524 patients. Both heterozygous
(*1/*17; n = 546) and homozygous (*17/*17; n = 76)
allele carriers had signiﬁcantly lower ADP-induced platelet
aggregation values as compared with wild-type homozy-
gotes. CYP2C19*17 allele carriage was also identiﬁed as
an independent risk factor of bleeding (odds ratio for car-
riers of at least 1 allele vs. noncarriers 1.85; 95% conﬁ-
dence interval 1.19–2.86; P = 0.006). However, no
signiﬁcant inﬂuence of CYP2C19*17 on the occurrence of
stent thrombosis was found [28].
Clinical consequences of ABCB1 polymorphism
Although the genetic variant 3435C?T of ABCB1 is
associated with impaired function of the intestinal drug-
efﬂux transporter, the data concerning its clinical signiﬁ-
cance remain inconclusive. Simon et al. [30] analyzing
patients presenting with myocardial infarction and receiv-
ing clopidogrel from a nationwide French registry found
that carriers of two variant alleles 3435C ? T of had a
higher rate of cardiovascular events (death from any cause,
nonfatal stroke, or myocardial infarction) at 1 year than
those with the ABCB1 wild-type genotype (CC at nucle-
otide 3435) (15.5 vs. 10.7%; adjusted hazard ratio 1.72;
95% conﬁdence interval 1.20–2.47). However, in an sub-
analysis of patient undergoing coronary angioplasty the
ABCB1 polymorphism was not an independent predictor of
outcome. Furthermore, recently published genetic sub-
studies of TRITON-TIMI 38 and PLATO trials demon-
strated contrasting results [43, 48]. Mega at al. [48] noted
an increased risk of recurrent ischaemic events in carriers
of two variant alleles 3435C?T treated with clopidogrel.
According to their observations, in healthy individuals such
genotype was linked with less platelet inhibition [48]. In
contrast, Wallentin at al. [43] observed even a numerically
higher rate of primary efﬁcacy events for the high-
expression group (patients with the ABCB1 3435 CC
genotype) who were on clopidogrel.
Mutations in the P2Y12 receptor
Besides CYP2C19 and ABCB1 mutations, polymorphism
of the P2Y12 receptor can at least theoretically cause
clopidogrel non-responsiveness. Cattaneo described several
infrequent genetically determined defects of the platelet
P2Y12 receptor leading to a mild-moderate bleeding
diathesis [49]. However, in a genetic analysis of the FAST-
MI registry including patients with an acute myocardial
infarction receiving clopidogrel therapy, none of the
selected single-nucleotide polymorphisms in the P2Y12
receptor was associated with a risk of an adverse
outcome [30].
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123Is it time for routine genotyping in patients
on clopidogrel therapy?
Most of commercially available genotyping assays are
precluded from clinical use for establishing the optimal
drug choice in the acute setting since they require sophis-
ticated methodology, highly-skilled staff and several day
period before the ﬁnal results are obtained. However, ﬁrst
point-of-care assays for the CYP2C19 genotyping, have
been recently introduced. They include the AmpliChip
Cyp450 test (Roche Diagnostics GmbH, Mannheim, Ger-
many), Inﬁnity (AutoGenomics, Carlsbad, CA, US), and
Verigene System (Nanosphere, Northbrook, IL, US). These
tests can be performed on small amounts of whole blood
with a turnaround time of about 3–8 h.
It should be also taken into account that platelet function
is dynamic in individual patients because of the inﬂuence
of variable external factors, while the inﬂuence of genetic
variants is intrinsically constant. Thus, it may be reason-
able to consider both genotyping and platelet function
measurement to assess ischaemic risk and to facilitate
antiplatelet therapy [50].
Finally,ithasnotbeenproveninprospective,adequately-
powered, randomized trials so far that a decision-making
process based on the genotyping of variants involved in the
clopidogrel metabolism improves clinical outcome. Several
suchprojects(ELEVATE-TIMI56,GIANT,RAPIDGENE,
TARGET-PCI) are currently ongoing.
Conclusions
Different combinations of genetic variants may generate
high interpatient variability in clopidogrel metabolism. The
genetically determined variability in clopidogrel metabo-
lism results in differences of clinical outcome in patients on
antiplatelet therapy with this drug. However, due to limited
data supporting this strategy, a routine adoption of geno-
typing into clinical practice to guide antiplatelet therapy
cannot be currently recommended.
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